April 2, 2019 / 5:52 AM / 8 months ago

BRIEF-Erytech Pharma Presents New Erymethionase Preclinical Findings

April 2 (Reuters) - ERYTECH PHARMA SA:

* ERYTECH SAID ON MONDAY IT PRESENTED NEW ERYMETHIONASE PRECLINICAL FINDINGS AT 2019 AACR ANNUAL MEETING

* RESULTS SUPPORT THE POTENTIAL FOR COMBINATION OF ERYMETHIONASE WITH CHECKPOINT INHIBITION

* ERYMETHIONASE, METHIONINE-GAMMA-LYASE (MGL) ENCAPSULATED INTO RED BLOOD CELLS, DEGRADES L-METHIONINE, AMINO ACID NUTRIENT NEEDED FOR TUMOR GROWTH AND METASTASIS

* WHEN COUPLED WITH ORAL VITAMIN B6 ADMINISTRATION, ERYMETHIONASE HAS DEMONSTRATED INCREASED MGL HALF-LIFE VERSUS FREE FORM OF MGL, PROLONGED PLASMA METHIONINE DEPLETION AND HAS SHOWN SIGNIFICANT TUMOR GROWTH REGRESSION IN MOUSE MODELS OF GLIOBLASTOMA AND GASTRIC ADENOCARCINOMA

* AS COMPARED TO SINGLE AGENT THERAPY ALONE, TUMOR GROWTH INHIBITION OF 57% AND A 52% INCREASE IN SURVIVAL WERE OBSERVED

* ANALYSIS OF ERYMETHIONASE-TREATED TUMORS REVEALED SIGNIFICANT METABOLIC CHANGES, PROVIDING INITIAL MECHANISTIC INSIGHT ON HOW ERYMETHIONASE SENSITIZES THE TUMOR TO ANTI PD-1 IMMUNOTHERAPY

* IN VITRO EXPERIMENTS DEMONSTRATING INCREASED STIMULATION OF IMMUNE CELLS WITH ERYMETHIONASE ALSO SUGGEST THAT OTHER IMMUNE CHECKPOINT INHIBITORS, SUCH AS ANTI-CTLA-4 MONOCLONAL ANTIBODIES, COULD BE GOOD CANDIDATES FOR FURTHER COMBINATION STUDIES

Source text for Eikon:

Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below